GSK in out-licensing deal with Boston Pharmaceuticals

18 March 2021
glaxo_gsk_glaxosmithkline_big

UK pharma major GlaxoSmithKline (LSE: GSK) will out-license and option programs to Boston Pharmaceuticals (NYSE: BSX) under a newly-announced agreement.

Boston will become a preferred GSK partner for select pre-Phase II programs. This new agreement builds on the relationship established in 2018 with the US biopharma’s acquisition of five programs from the London-based company.

"This agreement makes strong strategic sense as it helps us assess the potential of multiple early-stage programs and focus on progressing our own internal assets"Initially, GSK will out-license and option two programs to Boston, the first being GSK3903371, a monoclonal antibody targeting the interleukin-1 receptor accessory protein, a tumor-associated antigen driving tumor growth and immunosuppression.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology